New antibiotic combo tested in healthy volunteers – no cure yet
NCT ID NCT06733675
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-stage study tests a new antibiotic combination (ceftibuten-ledaborbactam) in 46 healthy adults aged 18-55. The goal is to check safety and how the drug moves through the body, not to treat any disease. Participants will stay at a clinic for several days and have follow-up visits. This research helps gather important safety data before testing in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION (DDI) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON, Clinical Research Phase I Unit
RECRUITINGLenexa, Kansas, 66219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- Could a new drug alter the fate of common medications?
- First look: can a new drug candidate pass early safety tests in humans?